Medication

Global Genito-Urinary Drugs Market Report (2021 to 2030) - COVID-19 Impact and Recovery - ResearchAndMarkets.com

Thursday, May 6, 2021 - 3:56pm

Asia Pacific was the second largest region accounting for 21% of the global genito-urinary drugs market.

Key Points: 
  • Asia Pacific was the second largest region accounting for 21% of the global genito-urinary drugs market.
  • Africa was the smallest region in the global genito-urinary drugs market.\nPharmaceutical companies are investing in development of new class drugs for treating overactive bladders (OAB).
  • Beta-3 adrenergic agonists are drugs which cause the bladder muscles to relax without causing side effects such as dry mouth.
  • This has led to increased demand for pharmaceuticals products, significantly impacting market growth during this period.\n"

Insights on the Musculoskeletal Disorders Drugs Global Market to 2030 - Identify Growth Segments for Investment - ResearchAndMarkets.com

Thursday, May 6, 2021 - 3:43pm

Combination therapy involves use of more than one medication or drug to treat a disease.

Key Points: 
  • Combination therapy involves use of more than one medication or drug to treat a disease.
  • These changes are related to data protection such as the European Union's General Data Protection Regulation (GDPR), changes to drug approval procedures and other regulatory changes.
  • The increase in patient pool due to rising geriatric population globally, contributed significantly to the growth of the market during the historic period.
  • This has led to increased demand for pharmaceuticals products, significantly impacting market growth during this period.\n"

Global Central Nervous System Drugs Market Report (2021 to 2030) - COVID-19 Impact and Recovery - ResearchAndMarkets.com

Thursday, May 6, 2021 - 3:35pm

Asia Pacific was the second largest region accounting for 22% of the global central nervous system drugs market.

Key Points: 
  • Asia Pacific was the second largest region accounting for 22% of the global central nervous system drugs market.
  • Africa was the smallest region in the global central nervous system drugs market.\nMany central nervous system drug manufacturers are collaborating with other manufacturers in the industry to share technical knowledge and improve product quality.
  • In October 2016, UCB Pharmaceuticals signed a partnership agreement with Evotec for the research and development of drugs for nervous disorders such as epilepsy, Parkinson's and Alzheimer's diseases.\nThe central nervous system drugs market was mainly driven by rapid growth in emerging markets in the historic period.
  • Thus, strong economic growth boosted the demand for central nervous system drugs and this drove the market during the historic period.\n"

Moleac Pte Ltd wins SBR National Business Award for Pharmaceuticals

Thursday, May 6, 2021 - 12:28pm

b'SINGAPORE, May 6,2021 /PRNewswire/ -- Moleac, a biopharmaceutical company based in Singapore, wins SBR National Business Award for Pharmaceuticals.\nMoleac is dedicated in finding, developing and commercialising new medicines for the unmet medical needs of patients suffering from central nervous system diseases and injuries.

Key Points: 
  • b'SINGAPORE, May 6,2021 /PRNewswire/ -- Moleac, a biopharmaceutical company based in Singapore, wins SBR National Business Award for Pharmaceuticals.\nMoleac is dedicated in finding, developing and commercialising new medicines for the unmet medical needs of patients suffering from central nervous system diseases and injuries.
  • Stroke not only endangers the lives of stroke survivors, but also burdens families with significant caretaking and financial expenses.
  • This would mean an improvement of day-to-day functioning of patients who have experienced a neurological condition.
  • A second IND was recently approved for MLC1501 in TBI.\n'

Moleac Pte Ltd wins SBR National Business Award for Pharmaceuticals

Thursday, May 6, 2021 - 10:59am

b'SINGAPORE, May 6,2021 /PRNewswire/ -- Moleac, a biopharmaceutical company based in Singapore, wins SBR National Business Award for Pharmaceuticals.\nMoleac is dedicated in finding, developing and commercialising new medicines for the unmet medical needs of patients suffering from central nervous system diseases and injuries.

Key Points: 
  • b'SINGAPORE, May 6,2021 /PRNewswire/ -- Moleac, a biopharmaceutical company based in Singapore, wins SBR National Business Award for Pharmaceuticals.\nMoleac is dedicated in finding, developing and commercialising new medicines for the unmet medical needs of patients suffering from central nervous system diseases and injuries.
  • Stroke not only endangers the lives of stroke survivors, but also burdens families with significant caretaking and financial expenses.
  • This would mean an improvement of day-to-day functioning of patients who have experienced a neurological condition.
  • A second IND was recently approved for MLC1501 in TBI.\n'

Drug Patents in Development Database Service 2021: US & International Patents, Including Active and Expired Patents - ResearchAndMarkets.com

Thursday, May 6, 2021 - 9:46am

b'The "Drug Patent Database Subscription: Drugs in Development" database has been added to ResearchAndMarkets.com\'s offering.\nThis subscription was created to answer a simple question: When do drug patents expire?

Key Points: 
  • b'The "Drug Patent Database Subscription: Drugs in Development" database has been added to ResearchAndMarkets.com\'s offering.\nThis subscription was created to answer a simple question: When do drug patents expire?
  • Your needs evolve as the industry keeps changing.
  • Since then dozens of additional datasets have been added by aggressive adaptation based on your needs.\nThis subscription for the Drugs in Development portion of the database offers information on:\nGlobal biopharmaceutical markets face constant change.
  • This helps you see opportunities and enrich your analysis, without overwhelming you with options or asking you to perform many searches.

Mindset Pharma Invited to Present at Canaccord Genuity 41st Annual Growth Conference

Wednesday, May 5, 2021 - 12:00pm

b'Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs.

Key Points: 
  • b'Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs.
  • Mindset was established in order to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs.
  • Mindset is developing several novel families of next generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin as well as its own proprietary compounds.
  • www.mindsetpharma.com\nThis news release contains certain "forward-looking information" within the meaning of applicable securities law.

Large Study Analyzes Two Different Classes of ADHD Drugs in Preschool-Age Children

Tuesday, May 4, 2021 - 10:30pm

The researchers found that both classes of drugs have benefits, with differing side effects, suggesting that decisions on which class of drugs to prescribe should be made based on individual patient factors.

Key Points: 
  • The researchers found that both classes of drugs have benefits, with differing side effects, suggesting that decisions on which class of drugs to prescribe should be made based on individual patient factors.
  • In contrast, children aged 5 to younger than 6 prescribed were likely to continue using the medication for longer if they were prescribed a stimulant.
  • "Future research should seek to learn more about the use of these classes of drugs in preschool-age children so that we can prescribe the most effective therapy for each patient.
  • In addition, its unique family-centered care and public service programs have brought the 595-bed hospital recognition as a leading advocate for children and adolescents.

Worldwide C5 Complement Inhibitors Drug Industry to 2026 - Detailed Profiles of Current Market Trends

Tuesday, May 4, 2021 - 6:00pm

b'DUBLIN, May 4, 2021 /PRNewswire/ -- The "Global C5 Complement Inhibitors Drug Market Opportunity, Drug Price, Sales & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com\'s offering.\nThis report provides comprehensive insight on clinical and non-clinical factors that are driving the global C5 Complement Inhibitors market and its impact on the global pharmaceutical market landscape.

Key Points: 
  • b'DUBLIN, May 4, 2021 /PRNewswire/ -- The "Global C5 Complement Inhibitors Drug Market Opportunity, Drug Price, Sales & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com\'s offering.\nThis report provides comprehensive insight on clinical and non-clinical factors that are driving the global C5 Complement Inhibitors market and its impact on the global pharmaceutical market landscape.
  • The report has been prepared in a view to deeply profile the current market trends along with the sales insight on 3 commercially available C5 Complement Inhibitors with their regional level revenue, market share and the clinical profile.\nGlobal C5 Complement Inhibitors Drug Market Opportunity: > USD 15 Billion\nGlobal C5 Complement Inhibitors Drug Market Absolute Growth: 65% (2017 -2020)\nGlobal C5 Complement Inhibitors Drug Market Growth In 2020: 21% (> USD 5 Billion)\nCommercially Available C5 Complement Inhibitors Drugs: 3 (Soliris, Ultomiris & Elizaria)\nSoliris (Eculizumab) Sales In 2020: > USD 3 Billion\nGlobal pharmaceutical marketplace is undergoing subtle changes with respect to the need of the patient population.
  • In addition, the global sales of the C5 complement inhibitor drug market is growing at steadily, apparently depicting the increase in the consumption rate of the drugs by the patients.
  • Exclusive demand of the therapeutic approach such as C5 complement inhibitor therapy and the presence of few inhibitor drugs in the market is also predicted to align the entire market toward becoming more dynamic and drastic.

Global Cell and Gene Therapy Contract Manufacturing Organizations (CMOs) Market Report 2021 with Profiles of Companies, Key Players, and Competitors in the Market - ResearchAndMarkets.com

Tuesday, May 4, 2021 - 3:31pm

b'Contract manufacturing is an increasing part of the pharmaceutical business. In cell therapy, this need is magnified because of the demand for cell and gene therapy products.\nThe report the Market for Cell and Gene Therapy Contract Manufacturing Organizations (CMOs) details the following:\n'

Key Points: 

b'Contract manufacturing is an increasing part of the pharmaceutical business. In cell therapy, this need is magnified because of the demand for cell and gene therapy products.\nThe report the Market for Cell and Gene Therapy Contract Manufacturing Organizations (CMOs) details the following:\n'